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We updated a field synopsis of genetic associations of cutaneous melanoma (CM) by systematically retrieving
and combining data from all studies in the field published as of August 31, 2013. Data were available from 197
studies, which included 83,343 CM cases and 187,809 controls and reported on 1,126 polymorphisms in 289
different genes. Random-effects meta-analyses of 81 eligible polymorphisms evaluated in44 data sets confirmed
20 single-nucleotide polymorphisms across 10 loci (TYR, AFG3L1P, CDK10, MYH7B, SLC45A2, MTAP, ATM,
CLPTM1L, FTO, and CASP8) that have previously been published with genome-wide significant evidence for
association (Po5 10 8) with CM risk, with certain variants possibly functioning as proxies of already tagged
genes. Four other loci (MITF, CCND1, MX2, and PLA2G6) were also significantly associated with 5 10 8
oPo1 10 3. In supplementary meta-analyses derived from genome-wide association studies, one additional
locus located 11kb upstream of ARNT (chromosome 1q21) showed genome-wide statistical significance with
CM. Our approach serves as a useful model in analyzing and integrating the reported germline alterations
involved in CM.
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INTRODUCTION
The incidence of cutaneous melanoma (CM), currently the
leading cause of skin cancer–related mortality, has increased
substantially over the past several decades in populations of
European descent (Nikolaou and Stratigos, 2014). About
5–10% of CM patients have a positive family history (Florell
et al., 2005), and family studies in twins have estimated that
B55% of the phenotypic variance is attributable to inherited
factors (Shekar et al., 2009). Although highly penetrant,
causative mutations in single genes, e.g., in CDKN2A/CDK4
and BAP1, have been identified in mainly familial cases of
cutaneous and cutaneous/uveal melanoma, respectively, they
only account for a small proportion of all cases (Tsao et al.,
2012; Hill et al., 2013). The majority of CM cases are likely
caused by the interaction of a few environmental factors, with
excessive exposure to UVR being the most prominent risk
factor, and dozens to hundreds common genetic variants that
individually exert moderate risk effects (Law et al., 2012;
Meng et al., 2012).
Numerous genetic association studies have been published
to date reporting on multiple polymorphisms as potential risk
factors for CM, including seven genome-wide association
studies (GWAS) on CM (Brown et al., 2008; Bishop et al.,
2009; Amos et al., 2011; Barrett et al., 2011; Macgregor et al.,
2011; Teerlink et al., 2012; Iles et al., 2013). This increasing
amount of data is more and more difficult to follow-up
and interpret. We previously created the freely available
online MelGene database (www.melgene.org, Chatzinasiou
et al., 2011), which provides a comprehensive qualitative
overview of all published genetic association studies in CM
and presents a meta-analysis of eligible polymorphisms that
have been assessed in at least four independent case-control
data sets.
In this study, we present a systematic field synopsis of
the currently available epidemiological data in the field of
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genetic associations of CM on the basis of a comprehensive
update of the MelGene database. To this end, we added all
eligible genetic association studies that have been published
within a time period of 37 months since our original publica-
tion (Chatzinasiou et al., 2011) and present an updated meta-
analysis of polymorphisms investigated in CM. All eligible
publications are cited at the online MelGene database.
RESULTS
Our PubMed literature search of 1,285 citations yielded a total
of 197 eligible studies (17 GWAS and 180 candidate-gene
studies), reporting on 1,126 single-nucleotide polymorphisms
(SNPs) across 289 genes. This included 51 additional studies
(43 candidate-gene studies and 8 GWAS) since our original
publication (Chatzinasiou et al., 2011) and 16 loci that were
included for the first time in our database. The median number
of polymorphisms assessed per study was 4.5 (interquartile
range: 2–16). The median sample size analyzed per poly-
morphism was 1,060 combined cases and controls (inter-
quartile range: 411–10,168). The most frequently analyzed
genes were MC1R (studied in 36 publications), ASIP
(13 publications), TYR (13 publications), and VDR (14 pub-
lications). Eighty-one SNPs met the inclusion criteria for meta-
analysis; 35 were derived from candidate-gene association
studies only, whereas 46 had available data from both
candidate-gene studies and GWAS and/or replication efforts
of GWAS signals.
Twenty SNPs across 10 independent loci (i.e., r2o0.30)
showed genome-wide significant evidence for association
with CM risk (Po5 10 8). Specifically, the most signifi-
cantly associated SNPs per locus were rs10931936 in CASP8
(on chromosome 2q33.1), rs16891982 in SLC45A2 (5p13.3),
rs401681 in CLPTM1L (5p15.33), rs7023329 in MTAP
(9p21.3), rs1126809 in TYR (11q14.3), rs1801516 in ATM
(11q22.3), rs4785763 in AFG3L1P (16q24.3), rs258322 in
CDK10 (16q24.3), rs16953002 in FTO (16q12.2), and
rs1885120 in MYH7B (20q11.22; Table 1, Supplementary
Table S1 online). This list includes three genome-wide signifi-
cant loci, i.e., ATM, FTO, and CASP8, identified by recent
studies (Barrett et al., 2011; Iles et al., 2013; Pena-Chilet et al.,
2013) published since our last field synopsis (Chatzinasiou
et al., 2011). Of note, rs4785763 and rs258322 were not in
notable linkage disequilibrium with each other (r2¼ 0.20);
thus, they are counted as independent loci in our synopsis.
The median summary odds ratio (OR) across all top inde-
pendent genome-wide significant signals was 1.20 (95%
confidence interval: 1.12–2.38). The median number of data
sets for SNPs included in each meta-analysis was six and the
median total sample size was 7,486.
In addition, meta-analyses across 24 SNPs yielded nomin-
ally significant evidence for association with CM risk (5
10 8oPo0.05). Four loci showed strong but sub-genome-
wide significant evidence for association (i.e., 5108
oPo1103): rs149617956 in MITF (3p13, OR¼ 2.34,
P¼2.5 106), rs11263498 in CCND1 (11q13.3, OR¼
1.11, P¼4.6 104), rs6001027 in PLA2G6 (22q13.1,
OR¼0.86, P¼7.54 107), and rs45430 in MX2 (21q22.3;
OR¼0.89, P¼ 1.07 10 5). Both rs11263498 and rs45430
showed ‘‘weak’’ credibility (grade ‘‘C’’), whereas the association
result of rs6001027 and rs149617956 showed only ‘‘moder-
ate’’ credibility (grade ‘‘B’’). The latter result is due to the fact
that this variant has a low minor allele frequency (i.e.,
MAF¼0.6%; Supplementary Table S1 online); thus, the
‘‘amount of evidence’’ for this meta-analysis is limited,
whereas the meta-analysis shows consistent effect size esti-
mates (I2¼ 0, 95% confidence interval: 0–85) across all four
included data sets and no indication of potential bias
(Ioannidis et al., 2007). The grading of the 20 remaining
SNPs yielding nominally significant but statistically weaker
evidence for association with CM risk upon meta-analysis
showed ‘‘strong’’ (grade ‘‘A’’) epidemiologic credibility for 3,
‘‘moderate’’ (grade ‘‘B’’) epidemiologic credibility for 4, and
‘‘weak’’ (grade ‘‘C’’) epidemiologic credibility for 13 variants
(Supplementary Table S1 online).
Supplementary meta-analysis
In addition to the main analysis on variants for which data of
at least four independent data sets were available, we
performed supplementary meta-analysis on variants for which
only three data sets derived from GWAS and/or GWAS
replication data sets were available (Supplementary Table S2
online). Upon meta-analysis of 72 SNPs, a polymorphism
located B11 kb upstream of ARNT on chromosome 1q21
(rs7412746; Macgregor et al., 2011) showed genome-wide
significant evidence for association with CM risk (OR¼0.87,
P¼91011; Supplementary Table S2 online).
Additional variants with genome-wide significance reported in
o3 data sets (not subjected to meta-analysis)
Furthermore, CM GWAS reported on additional SNPs across
two independent loci that showed genome-wide significant
evidence for association (Bishop et al., 2009; Amos et al.,
2011; Teerlink et al., 2012); however, these results were based
on o3 independent data sets, and thus no meta-analysis was
performed in our field synopsis. The most significantly
associated SNPs per locus were rs1129038 in HERC2 (on
chromosome 15q13.1, OR¼ 0.69, P¼ 2.58 108) and
rs17119490 located in an intergenic region on chromosome
10q25.1 (OR¼8.4, P¼7.211012; Supplementary Table
S3 online).
DISCUSSION
The MelGene database represents a comprehensive, system-
atically updated, online synopsis of genetic association studies
in CM (Chatzinasiou et al., 2011). This freely available data-
base is curated by experienced researchers to summarize the
volume of the evidence of association between genetic
variants and CM risk. To our knowledge, this is one of the
few field synopsis databases that is continuously updated since
its launch 37 months ago (Belbasis et al., 2014). Up to now
more than 1,000 SNPs across almost 300 genes impli-
cated in melanoma risk can be accessed and synthesized
wherever possible. This reflects the value of meta-analysis and
the accumulation of large sample sizes in the field of genetics
in minimizing the false-positive signals. Gathering empirical
evidence will allow greater insight in the assessment of
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cumulative evidence on genetic associations. Among others, it
may serve as an ideal resource for selecting the most
prominent risk variants to include in future risk prediction
models in an effort to improve risk stratification and cost-
effectiveness of screening campaigns (Cust et al., 2013).
Recent evidence supports the additive effect of common
genetic variants in predicting melanoma risk and their
potential use in enhancing the value of risk prediction
models that contain standardized phenotypic risk factors
(Fang et al., 2013; Stefanaki et al., 2013).
Our main meta-analysis yielded genome-wide significant
evidence for association with CM for 10 loci, including 3 loci
(ATM, FTO, and CASP8; Barrett et al., 2011; Iles et al., 2013;
Pena-Chilet et al., 2013) that were not included in our pre-
vious meta-analysis (Chatzinasiou et al., 2011). Moreover,
four loci (i.e., MITF, CCND1, PLA2G6, and MX2) showed
suggestive but sub-genome-wide significant association with
CM in our main analyses. The supplementary meta-analyses
confirmed one additional independent locus that showed
genome-wide significant association with CM (rs7412746
on chromosome 1q21; Amos et al., 2011), which was not
included in our previous meta-analyses. Even though a
number of independent signals were found to have a strong
association with melanoma in certain loci (Table 1), some of























5 1322087 CLPTM1L rs401681 10 1.19 (1.12–1.26) 1.42 10 08 A B 45 A A
9 12672097 TYRP1 rs1408799 7 0.91 (0.84–0.98) 0.012 A B 31.9 C Low
OR
C
9 21816528 (MTAP) rs7023329 6 0.83 (0.80–0.86) 1.11 10 25 A A 0 A A
9 21968159 CDKN2A rs3088440 8 1.27 (1.10–1.46) 0.0009 A A 0 C F, HWE C
15 28230318 OCA2 rs1800407 4 1.38 (1.09–1.74) 0.007 B A 0 A B
20 33576989 MYH7B rs1885120 5 1.55 (1.41–1.71) 1.60 10 18 A A 0 A A
5 33951693 SLC45A2 rs16891982 10 0.42 (0.35–0.50) 1.47 10 23 A A4 43 A4 A
22 38545619 PLA2G6 rs6001027 5 0.86 (0.80–0.91) 7.54107 A B 48.3 A B
21 42746081 MX2 rs45430 5 0.89 (0.85–0.94) 1.07105 A B 26 C Low
OR
C
12 48239835 VDR rs1544410 7 0.90 (0.83–0.96) 0.004 A A 10.8 C Low
OR
C
16 54114824 FTO rs16953002 14 1.16 (1.11–1.20) 3.61012 A A 0 A A
11 69382767 CCND1 rs11263498 4 1.11 (1.05–1.18) 4.6 10 4 A B 45 C Low
OR
C
3 70014091 MITF rs149617956 4 2.34 (1.64–3.34) 2.52106 B A 0 A B
11 89017961 TYR rs1126809 9 1.20 (1.14–1.26) 7.88 10 12 A A 11.7 A A
16 89755903 CDK10 rs258322 4 1.64 (1.44–1.86) 3.98 10 14 A A 0 A A
16 90066936 AFG3L1 rs4785763 4 1.35 (1.27–1.44) 1.05 10 20 A A 0 A A
13 103528002 XPG rs17655 4 0.91 (0.82–1.00) 0.043 A A 0 C Low
OR
C
11 108175462 ATM rs1801516 5 0.84 (0.79–0.89) 1.49109 A A 0 A A
2 202143928 CASP8 rs10931936 4 1.15 (1.09–1.21) 2.7 10 8 A A 8.5 A A
1 226564691 PARP1 rs3219090 4 0.86 (0.78–0.93) 0.0003858 A C 56.2 A C
Abbreviations: CI, confidence interval; F, statistical significance lost excluding first study; HWE, statistical significance lost excluding Hardy–Weinberg
equilibrium-violating studies in control subjects; low OR, an ORo1.15; MAF, minor allele frequency in controls when combining all eligible data sets; NA,
not applicable; No. of minor alleles, number of minor alleles in patients and control subjects combined across all included data sets; OR, odds ratio.
1‘‘Nearest gene’’ denotes the gene in the respective locus or the most proximal gene in the respective locus if the SNP itself does not map into a gene region. It
should be noted that these genes are not necessarily the genes that are functionally affected by the genetic association finding in this locus. The location is on
the basis of the Human Genome Build hg19.
2Allelic odds ratios, 95% confidence intervals, and P-values (two-sided) were calculated by the DerSimonian–Laird random-effects model.
3Each statistically significant meta-analysis result was graded according to the Human Genome Epidemiology Network Venice criteria. Venice grading: A,
grade A (strong epidemiological credibility); B, grade B (modest epidemiological credibility); and C, grade C (weak epidemiological credibility).
4Criterion does not apply to meta-analysis results if it remained genome-wide significant (Po5 108) after exclusion of the initial study.
If multiple polymorphisms showed a statistically significant association in the same locus, only the variant with the best Venice grading is listed here. When the
Venice grading yielded equivalent scores, the variant with the smallest P is listed.
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these genes may not represent true susceptibility variants but
may simply tag other genes within the same locus that have a
more biologically plausible association with melanoma. For
example, AFG3L1P and CDK10 genes on chromosome 16 and
MHY7B on chromosome 20 most likely tag the well-known
pigmentation genes of MC1R and ASIP, respectively (Bishop
et al., 2009); e.g., the polymorphism rs258322 in CDK10
(16q24.3) is in linkage disequilibrium with the red hair allele
of MC1R rs1805007, derived from data from the 1,000
Genomes (1KG) project (r2¼0.58).
Our results may contribute to a more comprehensive view
of the genetic architecture of CM predisposition. Polymorph-
isms in genes controlling melanogenesis such as MC1R,
SLC45A2, and TYR or loci encompassing relevant genes
(CDK10/AFG3LIP/MC1R, MYH7B/PIGU/ASIP), assessed pri-
marily by candidate-gene studies and later confirmed by CM
GWAS (Brown et al., 2008; Bishop et al., 2009), showed
genome-wide significant association with CM risk in our
analysis. In addition, genes involved in cell growth and
apoptosis, i.e., PLA2G6, tumor suppression, i.e., CDKN2A/
MTAP, or telomerase length, i.e., TERT-CLPTM1L, all of which
were recognized as nevus-associated genes through GWAS or
large-scale association studies (Falchi et al., 2009; Barrett
et al., 2011; Law et al., 2012), were supported as genome-
wide or nominally significantly associated variants with
melanoma in our analysis. Recent GWAS have reported on
several other putative CM risk loci such as ATM (11q22.3),
MX2 (22q22.3), PARP1 (1q42), CASP8 (2q33.1), and CCND1
(11q13.3; Amos et al., 2011; Barrett et al., 2011; Macgregor
et al., 2011). All these loci were included in our analysis,
yielding nominal significance (MX2, CCND1, and PARP1) or
genome-wide significance for association with CM (ATM and
CASP8). These genes may operate beyond the two best-
characterized clinical phenotypes (nevi and pigmentation) in
roles that affect DNA damage repair, cell cycle control, and
senescence (Law et al., 2012).
Several of the above listed loci have been functionally
investigated or have been implicated in the pathophy-
siology of cancers other than melanoma. SNP rs149617956,
which showed suggestive evidence for association with
CM in the MelGene meta-analysis, is a rare germline
variant of MITF (Yokoyama et al., 2011). Interestingly,
MITF has been implicated in melanoma oncogenesis by
regulating several genes that have a role in the develop-
ment, differentiation, cell-cycle regulation, melanin produc-
tion, and survival of melanocytes (Bertolotto et al., 2011;
Yokoyama et al., 2011; Ghiorzo et al., 2013). The results
of our analysis confirms the previously reported associa-
tion (Bertolotto et al., 2011; Yokoyama et al., 2011).
Functional studies have shown an impaired sumoyla-
tion of the MITF protein encoded by the minor
allele of rs149617956 and a differential regulation of several
of its targets, resulting in a gain-of-function role in
tumorigenesis (Yokoyama et al., 2009; Bertolotto et al.,
2011). To our knowledge, our study provides the first meta-
analysis of this variant, strengthening its statistical association
with melanoma risk after including a larger number of
available data sets.
A recent GWAS of the GenoMEL Consortium (Barrett et al.,
2011) reported association of rs1801516 in ATM, a DNA
damage response gene, with melanoma without an effect on
pigmentation or nevus phenotypes. The same variant also
modifies the risk for ionizing radiation-induced or sporadic
papillary thyroid carcinoma in addition to BRCA1 and p53
variants (Akulevich et al., 2009; Wojcicka et al., 2014).
Although association of ATM and risk of breast cancer has
been reported as well, this was not confirmed in a recent
meta-analysis (Gao et al., 2010). CASP8 is a member of the
caspase family that induces apoptotic cell death mediated by
FAS and FASLG (Li et al., 2008). Although the variant that
showed genome-wide significant association with CM
(rs10931936) has not been investigated for its functional
relevance to melanoma, other variants in CASP8, including
a nonsynonymous, putatively functional polymorphism
(rs1045485) encoding a D302H substitution, have been
associated with a variety of cancers––i.e., lung, colon, and
breast cancer (Yin et al., 2010). FTO has been associated with
multiple traits, including end-stage-renal disease, myocardial
infarction, osteoarthritis, and endometrial cancer, most of
which appear to be related to body mass index and obesity.
Rs16953002, located in intron 8 (in contrast to the known body
mass index-related variants that are located in intron 1) showed
genome-wide significant association with melanoma indepen-
dently of body mass index, suggesting a broader function of
FTO beyond body mass index and obesity (Iles et al., 2013).
Our approach in curating and analyzing the genetic asso-
ciation data has certain limitations. Missing data from original
studies, i.e., genotype summary data, effect size estimates, or
direction of effect, were commonly encountered problems that
were partially resolved by either comparing with reference
panels (1,000 Genomes, HapMap) or, in more rare cases,
contacting the authors of the original studies. Moreover, even
in studies in which the population comprises people of the
same descent, we cannot exclude a potential ethnic substruc-
ture that can introduce heterogeneity (Evangelou and
Ioannidis, 2013). Other issues included inherent methodo-
logical errors in the original studies such as errors in geno-
typing or sequencing, discrepancies in defining allele names
and difficulties in identifying data set overlaps. In addition, our
inclusion strategies were primarily based on study-level
summary data, precluding the possibility of more refined
analyses––i.e., inclusion of potential confounders, analysis of
gene–gene or gene–environment interactions, and de novo
imputation of genotypes. Moreover, our approach excludes
any dominant mutations or rare allele variants.
In summary, we present herein the update of our on-going
effort to systematically annotate and analyze all published
genetic association studies in melanoma. The online version of
Melgene (www.melgene.org) has been embedded with a
number of technical refinements that enable improved func-
tionalities (Athanasiadis et al., 2014). Our freely available,
user-friendly database serves as a useful model of quantitatively
and qualitatively assessing the impact of genetic variation in
melanoma risk, and it can also link emerging data on genetic
associations with other sources of information on the biology
of genes, gene–gene, or gene–environment interactions.
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MATERIALS AND METHODS
Literature searches, data extraction, and statistical analyses were
performed as previously described and are summarized here only
briefly (Chatzinasiou et al., 2011).
Literature search of eligible studies and data extraction
To identify potential association studies eligible for inclusion in
MelGene, we searched the PubMed database using the terms
‘‘melanoma AND associat*’’. In addition we searched the Human
Genome and Epidemiology Network Navigator (http://hugenavigator.
net/HuGENavigator) and the Melanoma Molecular Maps Project
(http://www.mmmp.org/MMMP) for additional publications. The last
literature search was conducted on 31 August 2013. Studies included
in MelGene had to meet the following criteria: (1) to evaluate the
association between CM and one or more polymorphisms in a case-
control setting, (2) to be published in a peer reviewed journal, and (3)
to be published in English.
We excluded studies without a healthy control group, studies of
patients with melanoma other than CM (such as uveal melanoma),
and studies that examined highly penetrant mutations that were only
presented in the patient and not in the control group. Family-based
studies and studies of polymorphisms in mtDNA were included in the
qualitative overview of the database but excluded from the statistical
analyses. Two loci were considered independent if r2o0.3 using 1KG
project for populations of European descent (Genomes Project C
et al., 2012). In those cases where linkage disequilibrium could
not be calculated, we consider an ‘‘independent locus’’ as the most
significant meta-analysis result in a region ±1 Mb.
From all eligible studies we extracted the first author’s name, the
year of publication, demographic details of the analyzed data sets,
names of polymorphisms analyzed, and the corresponding genotype
counts in cases and controls where available, or, alternatively, the
additive/allelic OR and standard errors (95% confidence intervals).
Both for candidate-gene studies and GWAS overlapping popula-
tions, we included only one study in the respective meta-analyses.
Whenever all data were available, the study with the largest sample
size was included. In cases where overlapping studies had the exact
same population, the first study was included in meta-analyses.
Database
Data of the updated analysis of our field synopsis have been
deposited to a dedicated online publicly available central repository,
the MelGene database (www.melgene.org). To facilitate the use of
the presented data, we have updated the front end of the database
and improved its functionalities including tools for automatic gen-
eration of random-effects meta-analysis plots in high resolution,
summary OR, and heterogeneity calculations, as well as tools suitable
for network analysis of the data.
Statistical analysis
Summary ORs and 95% confidence intervals were calculated for
each eligible polymorphism from study-specific additive/allelic ORs
on the basis of the DerSimonian and Laird (1986) random-effects
model. Heterogeneity was assessed using the I2 metric. Heterogeneity
is considered as low, moderate, high, and very high for values
between 0 and 24%, 25 and 49%, 50 and 74%, and 475%, respec-
tively. In addition to the main meta-analyses including all available
data sets, a number of sensitivity analyses were performed––i.e.,
excluding the initial study and data sets violating Hardy–Weinberg
equilibrium in the control group (Po0.05). Nominal statistical
significance was defined as Po0.05 and genome-wide statistical
significance as Po5 10 8. All statistical tests were two-sided.
Assessment of epidemiologic credibility
Assessments of the epidemiologic credibility of nominally significant
meta-analysis results were performed using the Venice Criteria, a
grading score developed by the Human Genome Epidemiology
Network (Ioannidis et al., 2008), as amended also to accommodate
GWAS (Khoury et al., 2009). This procedure has been described
previously (Chatzinasiou et al., 2011). Briefly, this grading score
assesses the amount of evidence by counting the number of minor
alleles, the consistency of replication by assessing the heterogeneity
using the I2 metric, and the protection from bias by assessing various
sources of potential bias, including small-study effects, deviation from
Hardy–Weinberg equilibrium, or loss of statistically significant asso-
ciation (Po0.05) on exclusion of the initial study. As a result, based
on the previous assessments, the overall epidemiological credibility of
a finding is either ‘‘strong’’ (grade ‘‘A’’), ‘‘moderate’’ (grade ‘‘B’’), or
‘‘weak’’ (grade ‘‘C’’). Genome-wide significant results are considered
to have strong credibility, regardless of any other features.
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